SCHEMBL7585953

SCHEMBL7585953

COc1cc(C(N)=O)c(F)c(C)c1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
NNMT P40261 2/20 0.36
PARP10 Q53GL7 2/20 0.35
PARP15 Q460N3 1/20 0.35
PARP14 Q460N5 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK10 P53779 1/20 0.35
SCN10A Q9Y5Y9 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GPR52 Q9Y2T5 1/20 0.34
CSF1R P07333 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1125460 0.88 SOS1 (0.37) SOS1KDM4EALDH1A1GLAGAA
SCHEMBL3394127 0.79 TERT (0.35) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL5500439 0.78 NNMT (0.41) KDM4EHTTLMNANNMTPARP10
SCHEMBL18000514 0.76 KDM4E (0.42) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL5191450 0.76 CYP1A2 (0.41) KDM4EALDH1A1HPGDHTTLMNA
SCHEMBL15190459 0.72 NNMT (0.45) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL1697089 0.72 LCK (0.41) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL5531782 0.71 KDM4E (0.42) KDM4EPARP10
SCHEMBL28143231 0.70 PARP10 (0.48) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL13254935 0.69 NNMT (0.47) KDM4EALDH1A1GLAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 SOS1 4772/4885KDM4E 1272/4885ALDH1A1 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.